N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels

Atherosclerosis

Volumn 119, Issue 1, 1996, Pages 99-106

  Wiklund, Olov ^a   Fager, Gunnar ^b   Andersson, Anders ^c   Lundstam, Ulf ^a   Masson, Parvesh ^b   Hultberg, Björn ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d Astra Draco ^*

Author keywords

Cysteine; Homocysteine; Lipoprotein(a); N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; HOMOCYSTEINE; LIPOPROTEIN A; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HOMOCYSTEINE BLOOD LEVEL; HUMAN; HYPERLIPOPROTEINEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0030050097     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05635-1     Document Type: Article

References (46)

1. Berg K. A new serum type system in man - the LP-system. Acta Pathol Microbiol Scand 1963;59:369.
2. McLean JW, Tomlinson JE, Kuang W-J et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;300:132.
3. Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904.
4. Berg K, Dahlen G, Frick MH. Lp(a) lipoprotein and pre-β-lipoprotein patients with coronary heart disease. Clin Genet 1974;6:230.
5. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758.
6. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. J Am Med Assoc 1986;256:2540.
7. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990;301:1248.
8. Wiklund O, Angelin B, Olofsson S-O, Eriksson M, Fager G, Berglund L, Bondjers G. Apolipoprotein(a) and ischemic heart disease in familial hypercholesterolemia. Lancet 1990;335:695.
9. Niendorf A, Rath M, Wolf K et al. Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions. Virschows Arch A Pathol Anat 1990;417:105.
10. Bihari-Varga M, Gruber E, Rotheneder M, Zechner R Kostner G. Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta. Arteriosclerosis 1988;8:51.
11. Sattler W, Kostner GM, Waeg G, Esterbauer H. Oxidation of lipoprotein Lp(a): a comparison with low density lipoprotein. Biochem Biophys Acta 1984;1081:65.
12. Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system. Thromb Haemostas 1990;63:331.
13. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lan M. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993;260:1655.
14. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G Hobbs H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52.
15. Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels: opposite effects after oestrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992;89:1161.
16. Edén S, Wiklund O, Oscarsson J, Rosén T, Bengtsson B-Å. Growth hormone treatment of growth hormone deficient adults results in marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993;13:296.
17. Carlsson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med 1989;226:271.
18. Armstrong VW, Walli AK, Seidel D. Isolation characterization and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a). J Lipid Res 1985;26:1314.
19. Fless GM, ZumMallen ME, Scanu AM. Isolation of apolipoprotein(a) from lipoprotein(a). J Lipid Res 1985;26:1224.
20. Gavish D, Breslow JL. Lipoprotein(a) reduction by N-acetylcysteine. Lancet 1991;337:203.
21. Kroon AA, Demacker PNM, Stelenhoef FH. N-acetylcysteine and serum concentrations of lipoprotein(a). J Intern Med 1991;230:519.
22. Ziment I. Acetylcysteine: a drug with an interesting past and a fascinating future. Respiration 1986;50(1):26.
23. Scanu AM, Pfaffinger D, Fless GM, Makino K, Eisenbart J, Hinman J. Attenuation of immunologic reactivity of lipoprotein(a) by thiols and cysteine-containing compunds. Structural implications. Arterioscler Thromb 1992;12:424.
24. Mudd SH, Levy LH. Disorders of transsulfuration. In: Stanbury JB, Wyngarden JB, Fredrickson DS, Goldstein JL, Brown MS, editors. The metabolic basis of inherited disease. New York NY: McGraw-Hill, 1983;522.
25. Rees MM, Rogers GM. Homocysteinemia: association of metabolic disorder with vascular disease and thrombosis. Thromb Res 1993;71:337.
26. Wiklund O, Fager G, Craig IH, Wilhelmsson C-E, Vedin A, Bondjers G. Alphalipoprotein cholesterol in relation to acute myocardial infarction and its risk factors. Scand J Clin Lab Invest 1980;40:239.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499.
28. Johansson S, Bondjers G, Fager G, Wedel H, Tsipogianni A, Olofsson S-O, Vedin A, Wiklund O, Wilhelmsen C. Serum lipids and apolipoprotein levels in women with acute myocardial infarction. Arteriosclerosis 1988;8:742.
29. Taddei-Peters WC, Butman BT, Jones GR, Venetta TM Macomber PF, Ransom JH. Quantification of lipoprotein(a) particles containing various apolipoprotein(a) isoforms by a monoclonal anti-apo(a) capture antibody and a polyclonal anti-apolipoprotein B detection antibody sandwich enzyme immunoassay. Clin Chem 1993;39:1382.
30. Andersson A, Isaksson A, Brattström L, Hultberg B. Homocysteine and other thiols determined in plasma by HPLC and thiol-specific post-column derivatization. Clin Chem 1993;39:1590.
31. Sjödin K, Nilsson E, Hallberg A, Tunek A. Metabolism of N-acetyl-L-cysteine; some structural requirements for the deacetylation and consequences for the oral bioavailability. Biochem Pharmacol 1989;38:3981.
32. Oscarsson J, Ottosson M, Wiklund O, Mårin P, Vikman K Björntorp P, Edén S. Low dose continuously infused growth hormone results in increased lipoprotein(a) and decreased low density lipoprotein cholesterol concentrations in middle-aged men. Clin Endocrinol 1994;41:108.
33. Oscarsson J, Lundstam U, Gustafsson B, Wilton P, Edén S, Wiklund O. Recombinant human insulin-like growth factor I decreases serum lipoprotein(a) concentrations in normal adult men. Clin Endocrinol. 1995;42:673.
34. Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989;83:137.
35. Franceschini G, Werba JP, Safa O, Gikalov I, Sirtori CR. Dose-related increase of HDL-cholesterol levels after N-acetylcysteine in man. Pharmacol Res 1993;2:213.
36. Hultberg B, Andersson A, Masson P, Larsson M, Tunek A. Plasma homocysteine and thiol compound fractions after oral administration of N-acetylcysteine. Scand J Clin Lab Invest 1994;54:417.
37. Borgström L, Kågedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Pharmacol 1986;31:217.
38. Borgström L, Kågedal B. Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing in man. Biopharm Drug Disp 1990;11:131.
39. Burgunder JM, Varriale A, Lautenberg BH. The effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989;36:127.
40. Mansoor MA, Svardal AM, Ueland PM. Determination of in vivo redox status of cysteine, cysteinyl glycine, homocysteine and glutathione in human plasma. Anal Biochem 1993;200:218.
41. Refsum H, Heiland S, Ueland M. Radioenzymatic determination of homocysteine in plasma and urine. Clin Chem 1985;31:624.
42. Wiley VC, Dudman NPB, Wilcken DEL. Interrelations between plasma free and protein-bound homocysteine and cysteine in homocystinuria. Metabolism 1988;162:191.
43. Harper PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89:10193.
44. Brattström L, Hardebo J, Hultberg B. Moderate homocysteinemia - possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 1984;15:1012.
45. Brattström L, Israelsson B, Norrving B, Bergqvist D Thörne J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51.
46. Brattström L, Israelsson B, Norrving B, Bergqvist D Thörne J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid. Atherosclerosis 1990;81:51.